[Analysis on point mutation of the CDKN2/p16 gene in lung cancer].
OBJECTIVE
To study the status of CDKN2/p16 gene point mutation in lung cancer.


METHODS
Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and sequencing were used to detect the point mutation of CDKN2/p16 gene exon 2 in 89 cases of lung cancer.


RESULTS
In 69 cases of the lung cancer without deletion of CDKN2/p16 gene exon 2, 16 cases were found to have suspicious abnormality of CDKN2/p16 gene exon 2 by PCR-SSCP, and in these 16 cases, 9 were found to harbor point mutations of CDKN2/p16 gene exon 2 by automated sequencing analysis.


CONCLUSIONS
The point mutation is one of the mechanisms for CDKN2/p16 gene inactivation, but it is not the chief mechanism. The inactivation of CDKN2/p16 gene aroused by point mutation plays a role to some extent in the genesis and progression of lung cancer.
Su
Changqing
C
Cancer Center of PLA, Nanjing 81 Hospital, Nanjing, Jiangsu, 210002 P. R. China. sucq@jlonline.com
Ye
Yukun
Y
Wang
Dong
D
Cao
Xiangrong
X
Li
Shufeng
S
Shan
Xiangnian
X
D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D005091:Exons; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D018807:Polymorphism, Single-Stranded Conformational; D017422:Sequence Analysis, DNA / Q000379:methods
D019941:Cyclin-Dependent Kinase Inhibitor p16